Filtered By:
Specialty: Endocrinology
Condition: Obesity
Drug: Metformin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 26 results found since Jan 2013.

The Impact of Metformin Use on the Cardiovascular Effects of DPP ‐4 Inhibitors: an Analysis of Medicare Claims Data 2007‐2015
ConclusionsIncidence rate differences in multiple cardiovascular outcomes appeared more favorable when DPP ‐4i initiation occurred in the presence of metformin, suggesting a possible interaction between DPP‐4i and metformin.This article is protected by copyright. All rights reserved.
Source: Diabetes, Obesity and Metabolism - November 20, 2018 Category: Endocrinology Authors: Matthew J. Crowley, Mugdha Gokhale, Virginia Pate, Til St ürmer, John B. Buse Tags: ORIGINAL ARTICLE Source Type: research

Metformin for the Management of Peri ‐operative Hyperglycemia
Perioperative hyperglycemia is an all too common issue (incidence 20‐40%) associated with significant surgical morbidity and mortality [1]. Often defined as a blood glucose >11.1mmol/L, peri‐operative hyperglycemia increases the risk for developing costly surgical site infections, sepsis, impairs wound healing, promotes endothelial dysfunction, thrombus formation, myocardial ischemia, stroke, neurocognitive dysfunction, prolongs length of hospitalization, and even death [2‐7].
Source: Diabetes, Obesity and Metabolism - November 9, 2017 Category: Endocrinology Authors: Russell Brown, James Paul Tags: LETTER TO THE EDITOR Source Type: research

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Conclusions/interpretationThere remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in...
Source: Diabetologia - August 2, 2017 Category: Endocrinology Source Type: research

Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care ‐based cohort study, with economic assessment of patient outcomes
ConclusionsWith respect to treatment choice, data from the present study support the notion of prescribing beyond metformin + SU, as alternative regimens have been shown to be associated with reduced outcomes risk and value for money.
Source: Diabetes, Obesity and Metabolism - February 22, 2017 Category: Endocrinology Authors: Jason Gordon, Phil McEwan, Marc Evans, Jorge Puelles, Alan Sinclair Tags: ORIGINAL ARTICLE Source Type: research

Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care based cohort study, with economic assessment of patient outcomes
ConclusionsWith respect to treatment choice, data from this study supports the notion of prescribing beyond M+SU, as alternative regimens have been demonstrated to be associated with reduced outcomes risk and value for money.
Source: Diabetes, Obesity and Metabolism - December 26, 2016 Category: Endocrinology Authors: Jason Gordon, Phil McEwan, Marc Evans, Jorge Puelles, Alan Sinclair Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular safety of glucose ‐lowering agents as add‐on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register
ConclusionsThis nationwide observational study showed that second‐line treatment with TZD and DPP‐4 inhibitor as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - July 18, 2016 Category: Endocrinology Authors: Nils Ekstr öm, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research

Comparative risk of major cardiovascular events associated with second ‐line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records
ConclusionsThiazolidinedione add‐on treatments to metformin were associated with lower risks of major cardiovascular disease or cardiovascular death compared with sulphonylurea add‐on treatment to metformin. Lower, but non‐statistically significant, risks were also found with DPP‐4 inhibitor add‐on therapies.
Source: Diabetes, Obesity and Metabolism - June 29, 2016 Category: Endocrinology Authors: S. S. Zghebi, D. T. Steinke, M. K. Rutter, R. A. Emsley, D. M. Ashcroft Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular Safety of Glucose‐Lowering Agents as Add‐on Medication to Metformin Treatment in Type 2 Diabetes:Report from the Swedish National Diabetes Register (NDR)
Conclusions: This nationwide observational study showed that second‐line treatment with TZD and DPP‐4i as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - May 31, 2016 Category: Endocrinology Authors: Nils Ekström, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research

Comparative risk of major cardiovascular events associated with second‐line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalisation and mortality records
ConclusionsThiazolidinedione add‐on treatments to metformin were associated with lower risks for major cardiovascular disease or cardiovascular death compared to sulphonylurea combination with metformin. Lower, but non‐statistically significant, risks were also found with DPP‐4i add‐on therapies.
Source: Diabetes, Obesity and Metabolism - May 12, 2016 Category: Endocrinology Authors: Salwa S Zghebi, Douglas T Steinke, Martin K Rutter, Richard A Emsley, Darren M Ashcroft Tags: ORIGINAL ARTICLE Source Type: research

Comparative cardiovascular safety of glucagon ‐like peptide‐1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RAs with other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to exclude large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - May 1, 2016 Category: Endocrinology Authors: E. Patorno, B. M. Everett, A. B. Goldfine, R. J. Glynn, J. Liu, C. Gopalakrishnan, S. C. Kim Tags: ORIGINAL ARTICLE Source Type: research

Comparative Cardiovascular Safety of Glucagon‐Like Peptide‐1 Receptor Agonists versus Other Antidiabetic Drugs in Routine Care: a Cohort Study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RA versus other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to rule out large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - March 23, 2016 Category: Endocrinology Authors: Elisabetta Patorno, Brendan M. Everett, Allison B. Goldfine, Robert J. Glynn, Jun Liu, Chandrasekar Gopalakrishnan, Seoyoung C. Kim Tags: Original Article Source Type: research

Case–control study of second‐line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke
ABSTRACT We conducted a population‐based case–control study to assess the myocardial infarction (MI) and stroke risks associated with sulfonylureas and insulin when used in combination with metformin. Cases had type 2 diabetes and used metformin + insulin or metformin + sulfonylureas at the time of a first MI or first stroke from 1995–2010; controls used the same treatment combinations and were randomly sampled from the same population. MI and stroke diagnoses and potential confounders were validated by medical record reviews. Compared with metformin + sulfonylurea, metformin + insulin was associated ...
Source: Diabetes, Obesity and Metabolism - July 14, 2015 Category: Endocrinology Authors: James S. Floyd, Kerri L. Wiggins, Colleen M. Sitlani, James H. Flory, Sascha Dublin, Nicholas L. Smith, Susan R. Heckbert, Bruce M. Psaty Tags: Research Letter Source Type: research

The brighter (and evolutionarily older) face of the metabolic syndrome: evidence from Trypanosoma Cruzi infection in CD‐1 mice
This article is protected by copyright. All rights reserved.
Source: Diabetes/Metabolism Research and Reviews - January 1, 2015 Category: Endocrinology Authors: Wunnie Brima, Daniel J. Eden, Syed Faizan Mehdi, Michelle Bravo, Mohammad M. Wiese, Joanna Stein, Vanessa Almonte, Dazhi Zhao, Irwin Kurland, Jeffrey E. Pessin, Tomas Zima, Herbert B. Tanowitz, Louis M. Weiss, Jesse Roth, Fnu Nagajyothi Tags: Research Article Source Type: research

Cardiovascular safety of combination therapies with incretin‐based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus – a retrospective nationwide study
ConclusionIncretin‐based drugs combined with metformin were safe compared with conventional combinations of glucose‐lowering therapy. Use of incretin‐based therapy may be target for strategies to lower CV risk in type 2 diabetes, although it should be recognized that the multivariable analysis may not have fully accounted for important baseline differences.
Source: Diabetes, Obesity and Metabolism - June 9, 2014 Category: Endocrinology Authors: U. M. Mogensen, C. Andersson, E. L. Fosbøl, T. K. Schramm, A. Vaag, N. M. Scheller, C. Torp‐Pedersen, G. Gislason, L. Køber Tags: ORIGINAL ARTICLE Source Type: research

Combination therapy with metformin plus sulphonylureas versus metformin plus DPP‐4 inhibitors: association with major adverse cardiovascular events and all‐cause mortality
ConclusionsThere was a reduction in all‐cause mortality for patients treated with metformin combined with DPP‐4i versus metformin plus SU, and a similar trend for MACE.
Source: Diabetes, Obesity and Metabolism - May 22, 2014 Category: Endocrinology Authors: C. Ll. Morgan, J. Mukherjee, S. Jenkins‐Jones, S. E. Holden, C. J. Currie Tags: ORIGINAL ARTICLE Source Type: research